SARS-CoV-2 antiviral therapy
The development of effective antiviral therapy for COVID-19 is critical for those awaiting
vaccination, as well as for those who do not respond robustly to vaccination. This review …
vaccination, as well as for those who do not respond robustly to vaccination. This review …
Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV
Since the beginning of the COVID-19 pandemic, large in silico screening studies and
numerous in vitro studies have assessed the antiviral activity of various drugs on SARS-CoV …
numerous in vitro studies have assessed the antiviral activity of various drugs on SARS-CoV …
Drug design and repurposing with DockThor-VS web server focusing on SARS-CoV-2 therapeutic targets and their non-synonym variants
The COVID-19 caused by the SARS-CoV-2 virus was declared a pandemic disease in
March 2020 by the World Health Organization (WHO). Structure-Based Drug Design …
March 2020 by the World Health Organization (WHO). Structure-Based Drug Design …
Rutin: A Potential Antiviral for Repurposing as a SARS-CoV-2 Main Protease (Mpro) Inhibitor
PK Agrawal, C Agrawal… - Natural Product …, 2021 - journals.sagepub.com
Various computational studies, including in silico ones, have identified several existing
compounds that could serve as effective inhibitors of the SARS-CoV-2 main protease …
compounds that could serve as effective inhibitors of the SARS-CoV-2 main protease …
Beneficial effects of a mouthwash containing an antiviral phthalocyanine derivative on the length of hospital stay for COVID-19: randomised trial
PS da Silva Santos, B da Fonseca Orcina… - Scientific reports, 2021 - nature.com
The risk of contamination and dissemination by SARS-CoV-2 has a strong link with nasal,
oral and pharyngeal cavities. Recently, our research group observed the promising …
oral and pharyngeal cavities. Recently, our research group observed the promising …
Progress and pitfalls of a year of drug repurposing screens against COVID-19
J Sourimant, M Aggarwal, RK Plemper - Current Opinion in Virology, 2021 - Elsevier
Near the end of 2019, a new betacoronavirus started to efficiently transmit between humans,
resulting in the current COVID-19 pandemic. Unprecedented worldwide efforts were made to …
resulting in the current COVID-19 pandemic. Unprecedented worldwide efforts were made to …
[HTML][HTML] Non-toxic dimeric peptides derived from the bothropstoxin-I are potent SARS-CoV-2 and papain-like protease inhibitors
MCLC Freire, GD Noske, NV Bitencourt, PRS Sanches… - Molecules, 2021 - mdpi.com
The COVID-19 outbreak has rapidly spread on a global scale, affecting the economy and
public health systems throughout the world. In recent years, peptide-based therapeutics …
public health systems throughout the world. In recent years, peptide-based therapeutics …
Identifying SARS-CoV-2 drugs binding to the spike fatty acid binding pocket using in silico docking and molecular dynamics
Drugs against novel targets are needed to treat COVID-19 patients, especially as SARS-
CoV-2 is capable of rapid mutation. Structure-based de novo drug design and repurposing …
CoV-2 is capable of rapid mutation. Structure-based de novo drug design and repurposing …
A potential antiviral against COVID-19 obtained from Byrsonima coccolobifolia leaves extract
In this study, we specifically focused on the crude methanolic leaf extract of Byrsonima
coccolobifolia, investigating its antifungal potential against human pathogenic fungi and its …
coccolobifolia, investigating its antifungal potential against human pathogenic fungi and its …
Inhibition of severe acute respiratory syndrome coronavirus 2 replication by hypertonic saline solution in lung and kidney epithelial cells
An unprecedented global health crisis has been caused by a new virus called severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). We performed experiments to test if a …
respiratory syndrome coronavirus 2 (SARS-CoV-2). We performed experiments to test if a …